A Study of ERAS-4001 in Patients With Advanced or Metastatic Solid Tumors.

ClinicalTrials.gov ID: NCT07021898

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT07021898. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 14, 2026, 9:31 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1 First-in-Human Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of ERAS-4001 Monotherapy and in Combination in Patients With Advanced Solid Tumors

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The main purpose of the study is to assess whether the study drug, ERAS-4001, is safe and tolerable when administered to patients with advanced or metastatic solid tumors with certain KRAS mutations. ERAS-4001 will be given alone or in combination with other treatments.

Study identification

NCT ID: NCT07021898
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1
Lead sponsor: Erasca, Inc.; Industry
Enrollment: 200 participants

Conditions and interventions

Conditions

Metastatic Solid Tumors

Interventions

ERAS-4001 Drug
ERAS-4001 in combination Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 99 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Aug 6, 2025 (Actual)
Primary completion: Aug 2028 (Estimated)
Completion: Dec 2028 (Estimated)
Last update posted: Dec 3, 2025

2025 – 2028

United States locations

U.S. sites: 5
U.S. states: 3
U.S. cities: 5

Facility	City	State	ZIP	Site status
Sarah Cannon Research Institute (SCRI) Oncology Partners	Nashville	Tennessee	32703	Recruiting
The University of Texas MD Anderson Cancer Center	Houston	Texas	77030	Recruiting
NEXT Oncology	Irving	Texas	75039	Recruiting
NEXT Oncology	San Antonio	Texas	78229	Recruiting
Fred Hutchinson Cancer Center	Seattle	Washington	98109	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07021898, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Dec 3, 2025 · Synced Nov 14, 2026